Quality that holds up
QMS built and remediated to ISO 13485 and 21 CFR 820 (QMSR) — design controls, CAPA, supplier quality, and audit readiness that survive inspection.
DP Dynamic Solutions is a quality, risk, and statistics consultancy for combination products and medical devices. We build the quality systems, risk management, and statistical evidence your product depends on — with regulatory support when you need it.
Quality systems, risk management & statistical evidence — across the total product lifecycle.
Our name is our method. Every engagement is built on the same four foundations — so nothing critical gets missed between the drug and the device.
QMS built and remediated to ISO 13485 and 21 CFR 820 (QMSR) — design controls, CAPA, supplier quality, and audit readiness that survive inspection.
ISO 14971 risk management, human factors (IEC 62366), FMEA, and benefit-risk analysis that satisfy reviewers and protect patients.
Study design, sample size, and statistical analysis — process capability, stability, and the evidence your claims stand on, with ALCOA+ data integrity throughout.
Advice means nothing without follow-through — systems built, findings closed, and evidence delivered. We stay until it's done.
Led by quality systems, risk management, and statistics — the disciplines that keep complex products compliant, defensible, and audit-ready.
QMS build, gap assessment, and remediation to ISO 13485 and 21 CFR 820 (QMSR) — CAPA, internal audits, supplier quality, and inspection readiness that holds up.
ISO 14971 risk management files, FMEA facilitation (dFMEA / uFMEA / pFMEA), and benefit-risk analysis woven into your design and clinical evidence.
Study design, sample size, and statistical analysis plans — process capability (Cpk), MSA / Gage R&R, stability, and acceptance sampling, with ALCOA+ data integrity.
Design controls under the QMSR (ISO 13485 Clause 7.3), design and development files, and IEC 62366 usability engineering through human-factors validation.
Integrated quality and risk across drug and device constituents under 21 CFR Part 4 cGMP — one coherent system, not two disconnected programs.
Support for your regulatory team — submission-readiness reviews, gap assessments, and the quality, risk, and statistical evidence that submissions depend on.
A drug-device combination isn't two projects — it's one regulated system. We integrate quality, risk, and data across both constituents so nothing falls between them.
No boilerplate. Every engagement follows a disciplined arc — so you always know where you are and what's next.
We map your product, quality system, and risk profile against the applicable standards — surfacing gaps early, while they're still cheap to fix.
You get a clear quality and risk roadmap — priorities, evidence plan, and timeline — built to hold up under audit.
We do the work: quality systems, risk files, statistical analysis, design controls, and human factors — leading it or embedding directly with your team.
Post-market surveillance, audit readiness, and change management keep you compliant long after launch.
Wherever a product touches both a therapy and a device, the regulatory questions get harder. That's exactly where we work.
"Combination products deserve advisors who understand both the drug and the device — and refuse to let anything fall between them."
Founder & Principal Consultant
DP Dynamic Solutions
DP Dynamic Solutions untangled a combination-product pathway we'd been stuck on for months. The strategy was clear, defensible, and — most importantly — it worked.
Book a 30-minute consultation. We'll talk through your product, your pathway, and the fastest defensible route to market.
No obligation · Direct with a principal consultant